|
|
Volumn 28, Issue 3, 2010, Pages 187-188
|
|
US biodefense contracts continue to lure biotechs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRAX IMMUNE GLOBULIN;
ANTHRAX MONOCLONAL ANTIBODY;
ANTHRAX VACCINE;
AV 7909;
CETHROMYCIN;
CIPROFLOXACIN;
ETI 204;
MDX 1303;
MONOCLONAL ANTIBODY;
POLYCLONAL ANTIBODY;
RESTANZA;
SMALLPOX VACCINE;
SPARVAX;
UNCLASSIFIED DRUG;
ANTHRAX;
ANTIBODY AFFINITY;
BIOLOGICAL WARFARE;
BIOLOGICAL WARFARE AGENT;
BIOTECHNOLOGY;
CLINICAL TRIAL;
CONTRACT;
DRUG INDUSTRY;
DRUG RESEARCH;
FUNDING;
GOVERNMENT REGULATION;
HUMAN;
LAW;
NOTE;
ORGANIZATION;
PATENT;
PRIORITY JOURNAL;
PRODUCT DEVELOPMENT;
SMALLPOX;
SOCIAL SECURITY;
UNITED STATES;
ANTHRAX;
BIOTECHNOLOGY;
BIOTERRORISM;
CONTRACTS;
DRUG INDUSTRY;
ECONOMICS, MEDICAL;
HUMANS;
UNITED STATES;
UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;
|
|
EID: 77749320889
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0310-187 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
